Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis
(DOSE-HD Trial)
Recruiting in Palo Alto (17 mi)
PA
Overseen byPete Antonopoulos, PharmD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Cook County Health
No Placebo Group
Approved in 3 Jurisdictions
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess whether the current recommendation for a 50% dose reduction in insulin for diabetic patients with a creatinine clearance (CrCl) ≤15 mL/min or on hemodialysis results in an increased number of hypoglycemic episodes.
Research Team
PA
Pete Antonopoulos, PharmD
Principal Investigator
Cook County Hospital
Eligibility Criteria
Inclusion Criteria
Inpatient men and women 18 years of age and older with a diagnosis of type 2 diabetes mellitus (T2DM) with CrCl ≥60, 16-59 or ≤15 milliliters/minute.
Treatment Details
Interventions
- Insulin (Hormone Therapy)
Insulin is already approved in Canada for the following indications:
Approved in Canada as Insulin for:
- Diabetes mellitus
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cook County Health
Lead Sponsor
Trials
47
Recruited
16,800+
John H. Stroger Hospital
Lead Sponsor
Trials
43
Recruited
13,100+